Company expects to have sufficient cash to fund planned operations beyond the FDA PDUFA goal date and anticipated fourth ...
INmune Bio's high-upside potential with CORDStrom for RDEB and XPro for Alzheimer's, offering up to 144.8x returns. Click ...